Related references
Note: Only part of the references are listed.Real-world data in the molecular erafinding the reality in the real world
D. J. Dickson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older
Sammy Saab et al.
HEPATOLOGY (2016)
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2016)
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
Graham R. Foster et al.
JOURNAL OF HEPATOLOGY (2016)
Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series
Tavankit Singh et al.
LIVER INTERNATIONAL (2016)
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection
C. Bunchorntavakul et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
Mehdi Najafzadeh et al.
ANNALS OF INTERNAL MEDICINE (2015)
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
Jagpreet Chhatwal et al.
ANNALS OF INTERNAL MEDICINE (2015)
Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C
Yousef Fazel et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C
Mario U. Mondelli
GASTROENTEROLOGY (2015)
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies
Fabien Zoulim et al.
GUT (2015)
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
Raymond T. Chung et al.
HEPATOLOGY (2015)
Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2015)
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Marc Bourliere et al.
LANCET INFECTIOUS DISEASES (2015)
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Masashi Mizokami et al.
LANCET INFECTIOUS DISEASES (2015)
Fake medicines are undermining global efforts to combat infectious disease, says US journal
Michael McCarthy
BMJ-BRITISH MEDICAL JOURNAL (2015)
Fake medicines are undermining global efforts to combat infectious disease, says US journal
Michael McCarthy
BMJ-BRITISH MEDICAL JOURNAL (2015)
New era for management of chronic hepatitis C virus using direct antiviral agents: A review
Tamer Elbaz et al.
JOURNAL OF ADVANCED RESEARCH (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
The New Era of Interferon-Free Treatment of Chronic Hepatitis C
Philipp Solbach et al.
VISZERALMEDIZIN (2015)
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
S. Saab et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Cost Analysis of Sofosbuvir/Ribavirin Versus Sofosbuvir/Simeprevir for Genotype 1 Hepatitis C Virus in Interferon-Ineligible/Intolerant Individuals
Liesl M. Hagan et al.
HEPATOLOGY (2014)
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Eric G. Meissner et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection
Huiying Rao et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treating Hepatitis C in Lower-Income Countries
Channa R. Jayasekera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study)
Francoise Degos et al.
JOURNAL OF HEPATOLOGY (2010)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
Hla-Hla Thein et al.
HEPATOLOGY (2008)
Diagnosis of cirrhosis by transient elastography (FibroScan):: a prospective study
J Foucher et al.
GUT (2006)
Estimation of utilities for chronic hepatitis C from SF-36 scores
HH Thein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C
M Ziol et al.
HEPATOLOGY (2005)
Share Paper
